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ABSTRACT: A novel one-step approach for designing non aggregated silica-based mesostructured 
therapeutic vectors is presented. Evaporation Induced Self Assembly was used in combination with 
amphiphilic drugs for preparing already loaded class I and class II hybrid materials containing from 50 
to 60 wt% (up to 75 vol%) of drug. A good mesostructuration was able to promote an interfacial control 
of the drug release in PBS medium with a complete absence of the initial burst release very often 
described in literature for water soluble drug release experiments. The investigation of both release 
mechanisms and matrix dissolution was conducted via in situ ellipsometry and NMR. It proved that the 
nature of the drug/matrix interaction, the chemical composition of the drug/matrix interface, as well as 
the mesostructuration quality parameters must be taken into account at the same time for tuning the drug 
release rate, while maintaining the dissolution rate of silica at a reasonable level for limiting its toxicity. 
It proved also that non-calcined as made silica-based class I hybrid materials can be efficiently used for 
tuning drug release kinetics from one hour to day scale.  
 INTRODUCTION 
The design of nanomaterials for drug transport and controlled release is a matter of utmost importance in 
biomedical science. Such therapeutic vectors, developed and tested in the last ten years, are aimed for 
accumulating in diseased tissues and deliver drug molecules at a tunable rate (Gref 1994, Brigger 2002, 
Horcajada 2008, Cheng 2009). The biodegradability of the employed material is a key parameter because of the 
potential risk of bioaccumulation and because of the influence of degradation kinetics on drug release rates 
(Pahaku Mitchell 2012, Soppimath 2001). Drug release from mesoporous silica-based vectors is particularly 
promising (Giri 2005, Vallet-Regi 2007, Rosenholm 2009, Liu 2009). Their tunable pore size and surface 
chemistry allow in principle a good drug/material surface interaction. Moreover, the easy functionalization of 
their external surface by organic moieties or polymers is a major advantage for site-specific targeting 
(Rosenholm 2010). and their degradation kinetics were proven accurately modulable in a large range by 
chemical modification of the silica matrix (Izquierdo-Barba 2010, Fontecave 2012, Pohaku-Mitchell 2012).  
In general, their mesoporous network is built by self-assembly of surfactant molecules and condensation of the 
inorganic matrix around this assembly. The resulting hybrid material is either washed (Vallet-Regi 2001) or 
calcined (Colilla 2010) so that mesopores are formed and are accessible for drug loading. The drug loading is 
then achieved by successive incubations of the particles in a concentrated solution of drug (Charnay 2004). 
Higher drug loads are usually achieved within highly porous silica carriers presenting mesopores larger than 4 
nm.  However, this method leads to a part of the drug molecules adsorbed onto their internal surface, and to 
another part weakly entrapped at the heart of mesopores. These latter are rapidly released by diffusion and cause 
an initial burst of drug release which is difficult to control (Song Langmuir 2005). In order to maintain high drug 
loads and to avoid the presence of these weakly bound molecules which release is hard to control, the mesopores 
size has to be finely tuned for each specific drug, which obliges materials scientist to design and optimize a 
specific inorganic vector for each drug (Horcajada 2004).  
Building a system in which a molecule is at the same time the structuring agent and the therapeutic agent 
represents an original approach in this field for it would allow the direct mesostructuration and encapsulating of 
high loads of drug, while insuring that each drug molecules interact in a similar way with the silica-based matrix. 
If the drug displays amphiphilic character, uncontrolled phase separation during sol-gel encapsulation can be 
avoided and the homogeneity of the material at the nanoscale is ensured by controlled nanosize separation of 
drug micelles within the inorganic or hybrid network. The three main advantages of this strategy are the 
 following: (i) a much simpler one step synthesis method  in which no calcination and no post drug loading is 
required (obviously favorable in terms of atom economy), (ii) high drug loading can be achieved (more than 50 
vol % according to usual syntheses of mesostructured silica with common structuring agents such as CTAB or 
nonionic surfactants), which decreases the amount of inorganic matrix in proportion, contributing to decrease its 
intrinsic toxicity , (iii) each drug molecule should interact in a similar manner with the silica-based wall. The 
release kinetic is thus in principle very easily tunable by modulating the drug-wall interaction and the 
degradation rate of the matrix. In this work, we investigated the validity of this concept by using three types of 
amphiphilic drug molecules: stearoyl choline iodide (SC), glucosyl resveratrol (GR) and sophorolipids (SL). 
Choline esters were shown to be potentially useful for the treatment of Alzheimer disease (Brevet Patel 2005, 
Alcaro 2010). Resveratrol is a natural molecule contained in red wine and may be related with the decrease in 
coronary heart disease observed among wine drinkers (French paradox) (Frémont 2000). Glycosylation of 
resveratrol protects it from enzymatic oxidation, increases its absorption and thus extends its lifetime in the cell 
(Regev-Shoshani 2001, Biasutto, 2009). Sophorolipids are microbial glycolipids obtained from the culture broth 
of Candida bombicola in presence of glucose and fatty acids (Van Bogaert 2007). Anticancer properties of these 
compounds have been proposed in the late 90’s (Scholz, 1998), and confirmed in more recent studies, 
sophorolipids influence the growth and apoptosis of H7402 human liver cancer cells (Chen, 2006). Their self-
assembling properties have been previously investigated in (Baccile 2010) and (Baccile 2012). These molecules 
have surfactant properties (Figure 1) and were used in the present work for synthetizing mesostructured silica or 
class II hybrid materials by Evaporation Induced Self Assembly (EISA). For comparing the properties of 
mesostructured materials made out of those molecules, we prepared both particles and films by evaporation 
Induced Self Assembly (EISA) (particles were made through aerosol route, and thin films were made by dip-
coating) (Brinker 1999, Boissiere 2011). Thin films were used as model systems for monitoring precisely by in 
situ ellipsometry the drug release and the degradation kinetics of the sol-gel matrix in undersaturation conditions 
of silica. Thanks to the low amount of matter involved with thin films experiments, we avoided the silica 
saturation and renucleation of silica particles or gel network detrimental for the comparison of the different drug 
systems investigated (details of the experimental protocol is described in the reference Fontecave 2012). 
  
 EXPERIMENTAL SECTION 
Sophorolipids synthesis. In this work we used the open acidic form of sophorolipids, as shown in Figure 1. The 
detailed synthesis of these compounds was described in a previous work [Baccile et al., Green Chem., 2010]. 
Glucosyl-Resveratrol biosynthesis: A mix of (3-OH)-α-glucosylated resveratrol and (4’-OH)-α-glucosylated 
resveratrol was synthesized by scaling-up the enzymatic reaction described in reference (Torres 2011). 
 
Figure 1: Drug molecules used for mesostructuring silica materials, A) stearoylcholine Iodide, B) 3-O-α-D-glucosyl 
resveratrol C) 4’-O-α -glucosyl resveratrol, D) open acidic form of sophorolipid 
Thin film synthesis: 
Thin films were made by sol-gel process. Initial sol compositions are described in the table 1. The sols were 
coated on silicon wafers by dip-coating, at a constant rate of 6 mm.s-1, in a 40% relative humidity atmosphere. 
Right after withdrawal, the sample is exposed to a 75% relative humidity atmosphere for 5 minutes. Films were 
then treated at 70°C for 2 days.  For GISAXS, ellipsometry and TEM analyses, films were calcined 30 minutes 
at 200°C and 10 minutes at 300°C, in the case of GR, 30 minutes at 200°C and 10 minutes at 400°C, in the case 
of SL and 30 minutes at 200°C and 20 minutes at 550°C, in the case of SC. 
Aerosol-made particles synthesis: 
Initial sol compositions are described in table 1. For stearoyl chloline and sophorolipids, the home-made aerosol 
apparatus described in reference (Julian-Lopez 2007) was used. Briefly, droplets are generated by a TSI-6 jet 
atomizer. They are led by an air flow through 50 cm-long 250°C-heated quartz tube in which they stay a few 
 seconds. Resulting solid particles were collected with a PTFE filter. For glucosyl-resveratrol, a low-temperature 
aerosol process was developed. The aerosol is generated from the sol and led by dry air to a 3 meter long - 0.6 
cm large - helical glass tube. The tube is thermostated at 60°C thanks to circulating warm oil. Before collection, 
the aerosol is bubbled in a 0.25 mol.L-1 solution of ammonia in water in order to improve the condensation of the 
outer silica part of the particles, so that the particles do not stick one to another onto the filter. 
Table 1 : Optimized Composition of solution used for the preparation of film and aerosol materials in presence of different 
drugs. 
  GR film SL film SL-MTEOS film SC film GR aerosol SL aerosol SC aerosol 
TEOS 1 1 0,7 1 1 1 1 
MTEOS - - 0,3 - - - - 
Drug 0,17 0,06 0,06 0,18 0,17 0,1 0,18 
H2O 5 5 5 5 20 25 50 
EtOH 60 60 60 60 20 25 600 
HCl  1,1 1,1 1,1 1,1 0,36 0,0046 11 
 
 
Characterizations. Grazing Incidence Small-Angle X-ray Scattering (GI-SAXS) was recorded using a Rigaku 
S-MAX 3000. Spectroscopic ellipsometry and Environmental Ellipsometric Porosimetry analyses were recorded 
with a M2000 Woolam ellipsometer equipped with a controlled atmosphere cell in which relative humidity was 
controlled by mass flow controllers (the setup and analysis protocol are described in reference Boissiere 2005). 
The analysis beam incidence angle was fixed at 70°. The modeling of the deposited sol-gel layers was performed 
with a simple Cauchy model. Transmission electron microscopy (TEM) was carried out using a JEOL 100 CX II 
microscope. TEM micrographs were processed with a slow scan CCD camera and analyzed with the Digital 
Micrograph program 
Degradation study. A dedicated in-situ ellipsometric analysis cell was developed for the degradation study. 
Briefly, the aim of this analysis being to directly monitor the degradation kinetic of mesoporous model layers in 
simulated biological medium, we built a double layer liquid cell containing 50 mL of PBS medium. The PBS 
temperature was controlled and maintained by liquid circulation of hot water within the walls of the liquid cell 
via an external thermostatic circulation pump. Two non-birefringent windows were adapted for allowing the 
light beam of the ellipsometer to pass. The real temperature of PBS was controlled by a thermocouple. For each 
experiment, the 1 cm2 film was introduced into the chamber after thermal equilibration and analysed 
 automatically every 60 seconds. All details of the experimental setup are given in the ref [described in paper of 
Thomas]. 
Drug release study. GR and SL: Drug release studies were made by UV spectroscopy by immersing 0.25 cm2 of 
thin film at the bottom of a quartz cell containing 3 mL of PBS (temperature is controlled with a thermostatic 
bath). The absorbance is measured in the PBS at 315 nm to quantify the glucosyl-resveratrol released in the 
aqueous medium, and at 260 nm for the sophorolipids. SC: 2 cm2 of thin film were immersed in 15mL of 
thermostated PBS. For each measurement, 0.5mL of the solution was taken off, dried and dissolved in deuterated 
methanol. 1H-NMR was performed on a Bruker AVIII 300 Spectrometer. Integration of SC terminal methyl peak 
(at 0.9 ppm) was compared to integration of CD2H-OD peak (at 3.35 ppm).  
In order to monitor silica dissolution, the volume fraction of silica was computed at each time of the analysis. At 
each time, a system of three equations with three unknowns was resolved. The three unknowns are fSiO2(t), 
fDrug(t) and fH2O(t) which are the volume fractions of silica, Glucosyl-Resveratrol and water, respectively. The 
three equations are:  
(i) BEMA [ fSiO2(t) , fDrug(t) , fH2O(t) ] = n(t) 
(ii) fDrug(t) = fDrug(0) . [ 1 – nfDrug(t) ] 
(iii) fSiO2(t) + fDrug(t) + fH2O(t) = 1 
where BEMA is the Bruggeman Effective Medium Approximation, n(t) is the refractive index of the thin film 
measured by ellipsometry and  nfDrug(t) is the normalized molar fraction of drug released, measured by in situ UV 
spectroscopy. The refractive index of the drug was computed with a standard Bruggemann Effective Medium 
Approximation between drug and silica, considering that the volume fraction could be deduced from the mass 
fraction and the densities of each component of the films. A dense silica film was made with the same low-
temperature thermal treatment for determining the refractive index of silica in the class I hybrid thin film. The 
variations of thickness were then considered to compute the remaining silica quantity, at each time. 
  
 RESULTS 
Structuration by Stearoyl Choline 
Stearoyl Choline (SC) templated very efficiently silica 
as thin films exhibiting a good quality 2D hexagonal 
mesostructure was obtained (as confirmed by GISAXS 
and TEM after calcination) (Figure 2A and SI 1). The 
d-spacing value for the p6m phase is 4.2 nm and is 
consistent with TEM image. For measuring the size of 
the drug domains issued from the EISA processing of 
these drugs, we calcined the film at 550°C for 20 
minutes and performed water adsorption-desorption 
followed by environmental ellipsometric porosimetry 
(EEP). The calcined matrix exhibited pore size of 2.1 
nm with a narrow pore size distribution, proving that 
this drug is able to form very homogeneous domains 
within the silica matrix (SI 2). Both the pore size and the 
2D hexagonal mesostructure observed by TEM are very 
similar to those obtained at the same concentration with 
CTAB surfactant, whose chemical structuture is very close to that of stearoyl choline molecule (Grosso 2004). 
The templating efficiency of SC is thus very high. The same process of structuration by EISA was used for 
preparing mesostructured particles by spray drying. The spherical nanosize particles obtained exhibited a worm 
like type mesostructure (Fig 2). The drug loading, directly controlled by the initial SC/TEOS molar ratio of the 
solution is, in this case, fairly high (60 wt%) if compared with drugs post impregnation in mesostructured 
materials of similar pore size (Vallet-Regi 2007 Angewandte) . If we assume that this drug behaves in a similar 
way than CTAB surfactant, the theoretical maximum load of such a vector (according to the maximum CTAB/Si 
molar ratio at which a mesostructure is reported by spray drying processing in literature) could be as high as 
73wt %. After calcination of the powder, the narrow pore size distribution observed by nitrogen physisorption 
analysis (Fig. 2C and SI 3) proved that SC still efficiently templates silica matrix as expected. As a consequence, 
the concept of direct drug templating is valid for making therapeutic silica-based nanovectors. 
Figure 2: TEM pictures of silica mesostructured by 
Stearoyl Choline via EISA in A) film and B) particle 
shapes. C) N2 physisorption isotherm of calcined 
particles. 
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 Structuration by Glucosyl-Resveratrol  
Glucosyl-Resveratrol (GR) templated silica thin films exhibit a poorly structured worm-like network. The pore 
size distribution obtained from water adsorption is broad (mainly between 2 and 6 nm) (SI 2). The d-spacing 
measured by GI-SAXS is around 7.2 nm (SI 1). The low quality of the mesostructuration is confirmed on TEM 
pictures by the presence of small stacks of short porous channels with a spatial average period of 7.5 nm. 
However, as nanosize domains observed are still in a 
few nanometers in size, the encapsulation mechanism 
is still likely to be due to a cooperative structuration of 
silica and GR whose micellization properties have 
been reported elsewhere (Torres 2011). The same 
process of structuration by EISA was used for 
preparing mesostructured particles by spray drying 
with high drug loading (52 wt %). The spherical 
nanosize particles obtained exhibited no apparent 
mesostructuration by TEM or SAXS (Fig. 3C). After 
calcination of the powder, a broad pore size 
distribution is observed by nitrogen physisorption 
analysis proving that aerosol processing of such 
molecule is perfectible (SI3). The origin of the low 
efficacy of GR in mesostructuring aerosol made 
particles comes probably from the two phenol groups 
of the hydrophobic tail which tend to interact with 
silica oligomers by hydrogen bonding, and make more difficult the formation of micelles in such synthesis 
conditions. Moreover, the formation of pre-micellar aggregates common for such molecules [Takaya Sakai,*,† 
Youhei Kaneko,† and Kaoru Tsujii Langmuir 2006, 22, 2039-2044 et Adv. Synth. Catal. 2011] is likely to slow down 
the formation of micelles during the EISA process. Finally, the solution evaporation being faster in spray drying 
(due to the presence of a significant amount of ethanol in the solution and dry air) than in film formation, the 
silica/GR seems to achieve mesostructuration only under slow evaporation conditions. As a conclusion, if the 
efficient encapsulation of high amount of GR is possible by EISA, the efficacy of using Glucosyl-Resveratrol 
Figure 3: TEM pictures of silica mesostructured by 
Glycosyl-Resveratrol via EISA in A) film and B) particle 
shapes. C) N2 physisorption isotherm of calcined particles. 
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 drugs for creating well defined drug domains with drug/matrix interactions-tunable release is still unclear from 
our data. 
Structuration by Sophorolipid  
Sophorolipid (SL) templated silica thin films exhibit a 
typical worm-like mesostructure. This was studied before 
and this is shown by the continuous ring-shaped signal 
observed on the GI-SAXS pattern (cf. SI 1) which 
indicated a correlation distance of 5 nm in the in-plane 
direction. The wormlike structure is confirmed by the 
corresponding TEM images on Figure 4A. The 
encapsulation by cooperative mesostructuration is 
confirmed by the narrow pore size distribution of 2.4 nm 
obtained by water physisorption of the calcined film (SI 
2). The same process of structuration by EISA was used 
for preparing mesostructured particles by spray drying. 
The SL-templated particles exhibit a worm-like 
mesostructure (see Figure 4B), as observed for the thin 
films. The drug loading of this vector is in such conditions 
of 51 wt% and can theoretically be increased between 56 and 60 wt% according to the SL/TEOS domain of 
mesostructuration reported in literature [Baccile 2010]. After calcination of the powder, nitrogen physisorption 
isotherm is characteristic of a super-microporous structure with pore size close to 1.8 nm diameter difficult to 
extract from BJH model (SI. 3). Hence in both film and aerosol materials, pore size distributions are compatible 
with an efficient templating of the silica matrix. As SL can efficiently form monodisperse nanodomains within 
aerosol particles, they can be used for testing the validity of drug/matrix interaction-controlled release. 
  
Figure 4: TEM pictures of silica mesostructured by 
Sophorolipid via EISA in A) film and B) particle 
shapes. C) N2 physisorption isotherm of calcined 
particles. 
 Drug release and degradation of thin films 
To compare drug release rates of different films produced in this study, we used Hill’s equation with good 
accuracy (results given in table 2). From these data we could simply analyse the various parameters and 
interdependencies of the drug/matrix/interaction/structuration system and extract the critical parameters.  
Table 2: Half release times of silica and drug obtained from Hill’s equation. 
 GR SL SL-MTEOS SC GR aerosol 
t1/2 drug release (min) 16 30 41 300 15 
t1/2 silica dissolution (min) 25 29 350 83 - 
 
1) Mesostructuration impacts drug release rates. 
Glucosyl-Resveratrol and Sophorolipids have the same type of hydrophilic glucose derivated head. They interact 
with the silica surface through hydrogen bonding. However, the SL release in PBS (pH=7.4) is about two times 
slower than GR release. It appears clearly that the mesostructuration quality has a strong impact on both drug 
release profile and kinetics (Fig. 5). The presence of aggregates in the GR-SiO2 architecture (evidences by the 
broad pore size distribution obtained from physisorption isotherms of powder and film) promotes an irregular 
Figure 5 : Drug and silica release profiles obtained in PBS solution at 37°C.  Glucosyl-Resveratrol (GR), Stearoyl Choline 
(SC), Sophorolipid (SL)  
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 release profile characterized by first bursts of GR release, followed by a more regular release profile that can be 
fitted by a standard Hill’s equation. Conversely, SL was shown to have a well-structured vermicular network 
promoting narrow domains size distribution within the silica matrix. In such a case, each SL molecule a priori  
interacts directly with the silica walls. It is remarkable to observe that the slower and more controlled SL release 
resulting only from the nanostructuration homogeneity can be observed for such a high drug loading (51 wt%). 
2) Drug/material interaction impacts drug release rates. 
Sophorolipid and Stearoyl-Choline templated silica thin films have the same type of cylindrical drug networks. 
In both cases, the great majority of drug molecules are in direct interaction with the inorganic surface.  However, 
the type of interaction between drug and silica is completely different in each case. In the case of SL, the sugar 
moiety is very likely to interact with the inorganic matrix by hydrogen bonding. In the case of SC, at pH=7.4 a 
strong electrostatic interaction exists between the positively charged quaternary ammonium head of the 
molecules and the negatively charged silanolate groups of the surface. This interaction leads to extremely slow 
drug release, with a half-time of 5 hours, and a total release after two days. Although not surprising, the strong 
impact of the drug/matrix interaction onto the release time is very interesting because it allows day scale release 
times with poorly condensed (non calcined) silica network, proving that the direct-drug-templating approach is a 
robust method for tailoring silica-based vectors with controlled dissolution/release kinetics. 
3) Drug/material composition impacts drug release rates 
By looking at the pure silica/SL system, one sees that half-times of silica dissolution and drug release have the 
same Hill’s equation release profile, suggesting that 
the progressive dissolution of the matrix is partially 
responsible for the SL release. Such a silica 
dissolution profile contrasts a lot with the linear 
dissolution profiles observed on pure mesoporous 
silica materials, proving that the drug/matrix 
interaction and/or the film composition and structure 
strongly impact the vector dissolution profile 
(Fontecave 2012). As already demonstrated in the 
same reference, the 30% methylated hybrid silica 
Figure 6 : In situ monitoring of film relative thickness as a 
function of PBS soaking time 
 matrix is much more stable towards hydrolysis than pure silica matrix. The experiments here reported confirm 
that this trend is maintained in presence of mesostructured drug domains, with dissolution of the SL-MTEOS30 
matrix being one order of magnitude slower than that of SL-TEOS. Although the interaction between SL and the 
30% mol methylated matrix can be expected to be weaker, the SL release from SL-MTEOS30 is also found 
slower (by about 35%) than from SL-TEOS, while still exhibiting a regular release profile as expected from a 
drug-mesostructured material with a narrow drug domains size distribution (SI 2). As a consequence, the 
drug/material interaction is not the only parameter influencing the drug release. If now one compares the 
evolution of the film thicknesses versus time in PBS, one realises that drug release mechanisms are more 
complex than “simple” diffusion-limited and/or dissolution assisted mechanisms (Fig. 6).  Indeed, the soaking in 
PBS medium promotes the swelling of the SL-based films while SC-based film thickness decreases with time. 
This strongly suggests that water molecules diffuse within SL-based films via the large silica/sophorose 
interphase which is able to dissolve high amount of water molecules. In a previous work, we have shown that the 
SL micelle/H2O interface is constituted by 90% of water (Baccile 2012). Under such conditions, water molecules 
are likely to be good competitors for sophorose/silanolates hydrogen bonds and thus to promote the fast release 
of sophorolipid molecules (Fig. 7). Such mechanism is coherent with the fact that the methylation of 30% of 
silica centres slows down the swelling of the film (thus the amount of water diffusing at the SL/silica interface) 
and slows down the release of sophorolipids molecules. A similar mechanism is probably responsible for the fast 
release of many hydrophilic species adsorbed within mesoporous silica materials in literature (captopril (Qu 
2006), gentamicin (Doadrio 2004)). By extension, 
this fast diffusion of water at the heart of the 
mesostructured material is likely to promote early 
dissolution of the silica matrix thus faster drug 
release. Saccharide molecules can condense with 
silica to form Si-O-C bonds when the hybrid 
material is treated above 110°C (Abdelmouleh 
2002, Castellano 2004). It was not observed in 
this study because we performed low-temperature 
thermal stabilization (70°C), but this effect can be 
considered for tailoring the release kinetics of 
saccharide derivatives. Conversely, the 
Figure 7: Scheme of water diffusion triggered release 
mechanism for Sophorolipids and StearoylCholine structuring 
agents. 
 hydrophilic Stearoylcholine/silica interface which is much narrower and less eager for water molecules does not 
facilitate their diffusion within the film (Baccile 2007). The progressive decrease of thickness suggests that the 
drug release mechanism at stake here is more related with a classical desorption of SC, probably followed by 
diffusion-triggered rearrangement of SC within the silica network. In such conditions, the dissolution of silica is 
slow at short time (dissolution at the external surface of the material) and progressively quickens as more 
internal surface is available for water. From the comparison of both systems, we learnt that if the strength of the 
drug/matrix interaction plays a major role in the drug release kinetic, strong modulations can be observed if 
water can diffuse and compete with it.  
 
In this work, we proved that EISA strategy was a simple, fast and efficient process for producing silica- based 
particles directly mesostructured by amphiphilic therapeutic molecules. In this context, many biologically active 
compounds (vitamins, hormones, flavonoids, antibiotics, etc.) contain glycosidic moieties and exhibit surfactant 
properties.When prepared by spray drying, already loaded and non-aggregated spherical particles were obtained 
in one step. Very high drug loads could be obtained (up to 60 wt% in this work) while maintaining sophorolipids 
and stearoyl choline structuring agents in monodisperse micellar domains periodically organized within the silica 
matrix. Even if the periodicity of the matrix is not necessarily the goal one should aim for in vectorization 
application, in this case it was shown to be a good quality criteria for promoting at the same time high 
amphiphilic drug loading an homogeneous drug/matrix interaction. This constitutes a strong improvement if 
compared with conventional silica-based mesoporous vectors that can hardly achieve both high loading and 
homogeneous drug/matrix interaction (Azais 2006). In addition, reaching very high drug loading impacts 
positively the global toxicity of the vector because much less inorganic material is used for their constitution. In 
parallel, we studied in situ both drug release kinetic and matrix dissolution in PBS medium. For that, drug-
templated films of similar composition were prepared by EISA. By coupling ellipsometry investigations and 
NMR analysis of PBS solution versus time, we could decorrelate silica dissolution and drug release and studied 
the influences and interdependency of the matrix mesostructure, structure and composition onto dissolution and 
release kinetics. We proved that a good mesostructuration quality coupled with the drug-templating approach 
(thus homogeneous drug/silica interaction) is able to eliminate completely the initial burst release very often 
described in literature in release experiments of water soluble drugs. In a similar way than with class II hybrid 
mesoporous silica, we showed that non covalent drug/silica interactions of such mesostructured class I hybrid 
material could present a wide range of release kinetics, from minutes in the case of sugar-based hydrophilic head 
 interacting with silica-based surfaces, to hours, in the case of strong electrostatic interaction. Both release and 
dissolution kinetics were found impacted by the structuring capacity of the drug, the capacity of the 
organic/inorganic interface to solubilize water and the composition of the matrix proving that the controlled 
design of a therapeutic vector has to be considered globally for tuning the drug release rate and the dissolution 
kinetic of the matrix.  
The direct drug templating approach presented here can be generalized to hydrophilic drug which can be 
functionalized with hydrophobic tails. Resulting molecules can have self-assembly properties (Couvreur 2008) 
and are also potential candidates for this novel strategy. Hydrophobic drugs are compatible with this approach as 
well. They can be solvated in the hydrophobic cores of bio-compatible surfactant micelles during the EISA 
process (Fatnassi 2010). Combined with the easy elaboration of class II hybrid materials and nano-composites by 
EISA, the direct drug templating is likely to promote in the near future a better method for mastering and tuning 
at the same time the complexity of drug/material interaction in liquid biological medium, and the intrinsic 
stability of the matrix that must be tuned for limiting its toxicity.  
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